← Back to Clinical Trials
Recruiting NCT06922409

NCT06922409 The Effects of Naturalistic Light on Post Stroke Complications Related Brain Areas in Stroke Patients During Admission for Rehabilitation.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06922409
Status Recruiting
Phase
Sponsor Rigshospitalet, Denmark
Condition Post Stroke Depression
Study Type INTERVENTIONAL
Enrollment 45 participants
Start Date 2025-04-10
Primary Completion 2026-04-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Naturalistic Light Intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 45 participants in total. It began in 2025-04-10 with a primary completion date of 2026-04-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Background: Light is the most important regulator of circadian rhythm. Naturalistic light, which contains the spectrum of sunlight throughout the day, has been shown to have a positive impact on mental states such as depression and fatigue in stroke and other diseases requiring long-term hospitalization. Depression and fatigue are very common complications after stroke, with a frequency of 30% and 85%, respectively. Both are significantly related to reduced quality of life and early death. Both the causes and pathophysiology behind these complications are unknown, but it is assumed that disturbances (inflammation and cell death) in brain areas and brain networks related to arousal, sleep, circadian rhythm, and the frontal lobe play a role. The hypothesis is that it is possible to detect changes in brain networks related to depression and fatigue by MRI, and that naturalistic light will affect these changes. Method: Stroke patients requiring a minimum of 10 days of rehabilitation are transferred to a neurorehabilitation unit with naturalistic lighting. Examination: Validated tests for fatigue, depression, sleep and cognitive functions. Pathophysiological studies: * MRI focusing on cerebral blood flow, metabolism, and cerebral networks. * Spinal fluid analyses for hormones and markers involved in immunological response as well as wakefulness/arousal and depression. * Sleep assessments.

Eligibility Criteria

Inclusion Criteria: * Patients scoring moderate-severe fatigue and/or depression OR NO fatigue and/or depressione which are evaluated as candidates for the rehabilitation unit. Exclusion Criteria: * GCS \< 15 * No functioning nervus opticus or retina in both eyes * Unable to open both eyes * Non communicating patients e.g. severe aphasia (incompetent patients) * Unable to cooperate to the physical examinations * Less than 10 days of hospitalization in the rehabilitation department * Claustrophobia * If the sub investigator finds the study participant unfit to conduct the investigations

Contact & Investigator

Central Contact

Anders Sode West, MD, PhD.

✉ anders.sode.west@regionh.dk

📞 +4538634051

Principal Investigator

Anders Sode West, MD, PhD

PRINCIPAL INVESTIGATOR

Glostrup University Hospital, Copenhagen

Frequently Asked Questions

Who can join the NCT06922409 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Post Stroke Depression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06922409 currently recruiting?

Yes, NCT06922409 is actively recruiting participants. Contact the research team at anders.sode.west@regionh.dk for enrollment information.

Where is the NCT06922409 trial being conducted?

This trial is being conducted at Glostrup Municipality, Denmark.

Who is sponsoring the NCT06922409 clinical trial?

NCT06922409 is sponsored by Rigshospitalet, Denmark. The principal investigator is Anders Sode West, MD, PhD at Glostrup University Hospital, Copenhagen. The trial plans to enroll 45 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology